Published in J Immunol on December 26, 2012
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis (2013) 1.25
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother (2014) 0.97
RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis (2014) 0.86
Molecular pathways: myeloid complicity in cancer. Clin Cancer Res (2014) 0.84
Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm (2013) 0.83
The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther (2015) 0.81
The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products. Oncoimmunology (2013) 0.80
Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene (2016) 0.79
The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: Implications for pancreatic cancer-driven immunosuppression. Oncoimmunology (2013) 0.77
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology (2015) 0.75
Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene (2016) 0.75
Rapid Detection of Neutrophil Oxidative Burst Capacity is Predictive of Whole Blood Cytokine Responses. PLoS One (2015) 0.75
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 5.23
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 3.91
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 3.00
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother (2011) 2.97
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Markers of mouse macrophage development detected by monoclonal antibodies. J Immunol Methods (1994) 2.85
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res (2011) 1.98
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol (2009) 1.96
The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev (2006) 1.90
Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol (2009) 1.61
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res (2011) 1.61
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med (2011) 1.52
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother (2011) 1.47
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J Leukoc Biol (2009) 1.37
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
Cell-mediated autophagy promotes cancer cell survival. Cancer Res (2012) 1.21
Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol (2009) 1.21
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol (2011) 1.13
Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin Biol Ther (2009) 1.12
Tumor-cell death, autophagy, and immunity. N Engl J Med (2012) 1.10
Chemokines in tumor development and progression. Exp Cell Res (2011) 1.08
Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol (2011) 1.07
Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men. Arch Pathol Lab Med (2009) 0.99
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer? Histopathology (2010) 0.85
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg (2013) 3.94
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
HMGB1 promotes drug resistance in osteosarcoma. Cancer Res (2011) 2.82
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 2.17
Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol (2006) 2.17
Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol (2002) 2.16
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood (2011) 2.05
Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res (2011) 1.98
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A (2009) 1.94
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine (2002) 1.92
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87
Robotic-assisted major pancreatic resection and reconstruction. Arch Surg (2010) 1.82
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med (2004) 1.80
Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs (2009) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer (2010) 1.70
UV irradiation resistance-associated gene suppresses apoptosis by interfering with BAX activation. EMBO Rep (2011) 1.68
A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med (2008) 1.62
Arginine and immunity. J Nutr (2007) 1.62
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics (2005) 1.56
Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res (2008) 1.53
Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol (2008) 1.52
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol (2010) 1.48
Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J Immunol (2007) 1.48
Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy (2011) 1.47
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res (2012) 1.46
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol (2013) 1.46
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett (2004) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol (2007) 1.43
A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods (2002) 1.42
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med (2002) 1.41
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol (2005) 1.39
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol (2011) 1.33
Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Res (2009) 1.32
Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol (2009) 1.32